Patent highlight: carboxamide PKMYT1 inhibitors for replication-stress cancers
- PKMYT1 restrains CDK1 at the G2/M checkpoint, and blocking it forces premature mitotic entry, DNA damage accumulation and cancer cell death.
- The patent overview covers the design, synthesis and therapeutic potential of a new carboxamide-based inhibitor series.
- The authors note potential to enhance ATR inhibitors, PARP inhibitors, chemotherapy and radiotherapy.
💡 Points
This is patent-literature triage rather than data, so I read it as competitor intelligence: a carboxamide chemotype arriving in a PKMYT1 field already crowded with quinazolines says IP space is being carved up fast. I'd go straight to the examples to check the hinge binder and how hard the series leans on the PARP/ATR combination angle.
Novel Carboxamide-Based PKMYT1 Inhibitors for Replication Stress-Associated Cancers ↗